Xie et al. demonstrated that downregulation of the SUMO-specific protease SENP2 in MM activates NF-κB by regulating the SUMOylation of IκBα, leading to bortezomib resistance [130]. The gene discussed is NFKB1; the disease is Miyoshi myopathy.